

#### <sup>24</sup>**Abstract**

<sup>25</sup>Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a multisystemic disease of 26 unknown aetiology that is characterised by disabling chronic fatigue and involves both the 27 immune and gastrointestinal (GI) systems. Patients display alterations in GI microbiome with 28 a significant proportion experiencing GI discomfort and pain and elevated blood biomarkers 29 for altered intestinal permeability compared with healthy individuals. To investigate a 30 possible GI origin of ME/CFS we designed a feasibility study to test the hypothesis that <sup>31</sup>ME/CFS pathogenesis is a consequence of increased intestinal permeability that results in <sup>32</sup>microbial translocation and a breakdown in immune tolerance leading to generation of 33 antibodies reactive to indigenous intestinal microbes. Secretory IgA and serum IgG levels 34 and reactivity to intestinal microbes were assessed in five pairs of severe ME/CFS patients 35 and matched same-household healthy controls. For profiling serum IgG we developed IgG-<sup>36</sup>Seq which combines flow-cytometry based bacterial cell sorting and metagenomics to detect <sup>37</sup>mucosal IgG reactivity to the microbiome. We uncovered evidence for immune dysfunction 38 in severe ME/CFS patients that was characterised by reduced capacity and reactivity of serum <sup>39</sup>IgG to stool microbes, irrespective of their source. This study provides the rationale for 40 additional studies in larger cohorts of ME/CFS patients to further explore immune-41 microbiome interactions.

<sup>43</sup>Keywords: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), antibodies, <sup>44</sup>immunoglobulin G, immunoglobulin A, microbiome, autologous, heterologous, immune tolerance, 45 leaky gut.

## <sup>46</sup>**Introduction:**

<sup>47</sup>Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is characterised by disabling <sup>48</sup>fatigue and autonomic, muscular, cognitive, neurological and immune symptoms that leave 49 patients unable to undertake their pre-morbid work, education, exercise and social activities<sup>1</sup>. 50 A quarter of diagnosed patients are house- or bedbound<sup>2</sup> and less than 5% ever recover their 51. pre-morbid activity levels<sup>3</sup>. A meta-analysis based on 45 studies estimated an average 52 population prevalence of 0.68% (95%CI = 0.48 to 0.97)<sup>4</sup>. However, these estimates vary 53. considerably by population and case definition<sup>4</sup>. The prevalence is anticipated to rise 54 following the COVID-19 pandemic as 45.2% of long COVID patients fulfil ME/CFS 55. diagnostic criteria<sup>5</sup>. The most common trigger of ME/CFS is an infection, while other 56 reported triggers include physical or mental trauma and toxin exposure<sup>3</sup>.

57 Several factors have been implicated in ME/CFS pathogenesis involving the immune <sup>58</sup>(autoimmunity, inflammation and chronic infection), gastrointestinal (GI), neurological, 59 endocrine and metabolic systems<sup>6</sup>. Between 38 and 92% of ME/CFS patients report co-60 morbid GI disturbances such as  $IBS^{3,7-9}$  and 35% of patients take medication for GI 61 disturbances including pro- and prebiotics, digestive enzymes and sodium bicarbonate<sup>3</sup>. The 62 high co-occurrence of ME/CFS and IBS suggests possible involvement of the intestinal <sup>63</sup>microbiome. Consistent with this possibility several studies have reported changes in the 64 community structure of the stool microbiome of ME/CFS patients exemplified by reduced 65 diversity<sup>8</sup> and decreased abundance of short-chain fatty acid producing bacterial species<sup>8-12</sup>. <sup>66</sup>ME/CFS patients may also have elevated biomarkers associated with increased intestinal 67 permeability $8,13,14$ . Intestinal inflammation and increased permeability can compromise <sup>68</sup>immune and microbial tolerance (defined as a state of hypo responsiveness to autologous 69 intestinal microbes)  $15$  leading to hyperreactivity and serum antibody production to 70 autologous intestinal microbes<sup>16</sup>; this can pre-stage autoimmune disease<sup>17</sup>. Of note, ME/CFS

71 patients displaying increased intestinal permeability have a higher incidence of serotonin 72 autoimmunity $18$ .

73 Based upon these observations we hypothesised that ME/CFS pathology is a 74 consequence of the breakdown in immune tolerance resulting from the increased intestinal 75 permeability and microbial translocation that leads to generation of antibodies reactive to <sup>76</sup>autologous intestinal microbes. In support of this proposal, a previous study found that, 77 compared with healthy controls, ME/CFS patients had abnormally high levels of IgA and 78 IgM produced in response to a panel of seven gram-negative enterobacteria<sup>13</sup>. However, this <sup>79</sup>small panel of microbes does not reflect the complexity of the intestinal microbiota which 80 comprises 300-500 bacterial species as well as viruses, archaea and fungi<sup>19</sup>. In addition, IgM 81 antibodies have low specificity for antigens<sup>20</sup> and IgA is primarily produced at mucosal  $s2$  sites<sup>21</sup>. Serum IgG reactivity to the microbiome in ME/CFS patients has recently been 83 investigated using phage immunoprecipitation sequencing (PhIP-Seq) to screen IgG 84 reactivity to 244,000 bacterial and viral epitopes<sup>22</sup>. This study is, however, restricted to 85 identifying antibody reactivity to peptide antigens and cannot detect reactivity to the 86 immunogenic glycoproteins and lipoproteins that decorate the outer membrane and surface of 87 bacterial cells, viruses and fungi<sup>23</sup>. Furthermore, none of the approaches used to date provide 88 information on whether immune tolerance to indigenous intestinal microbes is lost in <sup>89</sup>ME/CFS.

<sup>90</sup>To begin to address this important question and assess the systemic humoral immune 91 response to indigenous microbes we adapted 'IgA-Seq', a method that combines flow-92 cytometry-based bacterial cell sorting and 16S rRNA sequencing to detect mucosal IgA 93 reactivity to the microbiome<sup>24</sup>, to characterise serum IgG reactivity to the microbiome; we 94 refer to this new method as IgG-Seq. To evaluate the IgG-Seq protocol, we designed a <sup>95</sup>feasibility study with a small cohort of severe ME/CFS patients and healthy controls from the

<sup>96</sup>same households. The difficulty in accessing housebound or bedbound patients is a major 97 obstacle to understanding the pathophysiology and aetiology of ME/CFS and is why only 98. 0.5% of ME/CFS research is undertaken in severely affected patients<sup>2</sup>. One aim of this study, 99 therefore, was to assess the feasibility of, and barriers to, including severe ME/CFS patients 100 in research involving the collection of biological samples.

101

<sup>102</sup>**Results:** 

#### <sup>103</sup>*Recruiting severe ME/CFS patients and same household controls*

104 Study participants were recruited from the CFS clinic at Epsom and St Helier University <sup>105</sup>Hospitals (ESTH), Carshalton, UK and the ME/CFS service at East Coast Community 106 Healthcare Centre, Lowestoft, UK which together had 3,812 registered patients. Recruitment 107 began in October 2017, with the intention of recruiting ten severe house- or bedbound <sup>108</sup>ME/CFS patients and ceased in April 2020 due to the COVID-19 pandemic. Thirty-six 109 patients were invited to the study with a response rate of 58.3% (Supplementary Fig. S1). Of 110 those who responded, 42.9% were ineligible due to either the absence of a household control 111 (n = 4), failure to meet other inclusion criteria (n = 4) or were unable to provide written 112 informed consent  $(n = 1)$ . Of the 12 eligible pairs of participants, six provided informed 113 consent. The consenting appointments for the other six eligible participants were delayed 114 either due to patients rescheduling their appointments when feeling unwell, or the non-115 availability of phlebotomists to attend home visits. Consequently, consenting appointments 116 were delayed by up to 12 months for participants, by which point three patients either saw 117 their health further deteriorate preventing them from participating in the study, or acquired an 118 additional health complication that excluded them from the study. We received no further 119 communication from the remaining three pairs.

#### <sup>120</sup>*Study population characteristics*

<sup>121</sup>Samples were collected from five pairs of participants; one pair consented immediately prior 122 to the COVID-19 pandemic which prevented us from obtaining their samples (Table 1). The 123 recruited patients comprised four females and one male (mean age 33.8 years; standard <sup>124</sup>deviation (SD) 13.8). There was clinical heterogeneity amongst patients, with variation in the 125 age at which ME/CFS onset occurred, length of illness and symptom severity. Three patients 126 reported ME/CFS onset following a viral infection, one following vaccination and one 127 following surgery. IBS was reported in all patients but in none of their matched household 128 controls. Same household healthy controls included four males and one female (mean age 129 40.4 years; SD 16.7) who were the carers and spouse  $(n = 3)$ , parent  $(n = 1)$  or sibling  $(n = 1)$ 130 of the patients.

# <sup>131</sup>*Stool consistency does not separate severe ME/CFS patients with IBS from matched*  <sup>132</sup>*household controls without IBS*

133 Despite all ME/CFS patients, and no household controls, reporting IBS there was no evidence 134 for a difference in consistency of the collected stool samples between patients and controls, 135 as measured by the Bristol stool form scale (BSFS) or by water content (Fig. 1A and 1B). 136 Three controls had abnormally loose stools (BSFS 5-7) indicative of diarrhoea and one 137 control had an abnormally hard stool (BSFS 2) indicative of constipation. In contrast, two 138 patients had stool samples defined as having a healthy consistency (BSFS 3-4), one patient 139 had an abnormally loose stool (BSFS 5) and two patients had abnormally hard stools (BSFS  $140$  1-2).

## <sup>141</sup>*Assessment of secretory IgA in stool*

142 The concentrations of microbe bound  $IgA1/2$  (Fig. 2A) and free  $IgA1/2$  (Fig. 2B) were 143 measured by ELISA with no evidence of a significant difference between severe ME/CFS

144 patients and their matched household controls. Flow cytometry was used to determine the <sup>145</sup>distribution of IgA coating on stool microbes (Fig. 3A and 3B). When comparing the 146 proportion of stool microbes coated by IgA there was no evidence of any differences between 147 patients and matched controls (Fig. 3C). Based on the microbial load of stool samples <sup>148</sup>(Supplementary Fig. S2) the relative quantification of IgA bound microbes was converted to 149 absolute values which again revealed no evidence of differences between patients and 150 matched controls in the quantity of IgA coated microbes within stool samples (Fig. 3D).

## <sup>151</sup>*Severe ME/CFS patients have a reduced serum IgG immune response to stool microbes*

152 To determine whether immune tolerance to intestinal microbes was altered in severe ME/CFS 153 patients the level of serum IgG antibodies bound to both their own (autologous) stool <sup>154</sup>microbes and to non-self (heterologous) stool microbes from other individuals were measured 155 in patients and their matched household controls (Fig. 4A). Four patients had lower serum 156 IgG reactivity to indigenous stool microbes than their matched household controls ( $p =$ <sup>157</sup>0.07322) and all patients had lower serum IgG reactivity to foreign stool microbes than their 158 matched household controls ( $p = 0.006334$ ) (Fig. 4B). Furthermore, there was evidence for 159 controls having higher serum IgG reactivity to heterologous (patient) stool microbes than 160 serum IgG reactivity to autologous stool microbes ( $p = 0.0317$ ). In contrast, for patients there <sup>161</sup>was no evidence for a difference in serum IgG reactivity to autologous and heterologous 162 (control) stool microbes ( $p = 0.3619$ ). In addition, serum IgG reactivity to patients <sup>163</sup>(heterologous) stool microbes in control individuals was higher than serum IgG reactivity to 164 autologous stool microbes in patients ( $p = 0.003751$ ). A paired t-test of the averaged IgG <sup>165</sup>levels to indigenous and foreign stool microbes within individuals suggests that patients had a <sup>166</sup>lower IgG reactivity to stool microbes than controls irrespective of the source of the microbes  $167$  (p = 0.0185). Of note, the reduced levels of patient IgG antibodies to indigenous and foreign 168 stool microbes were not due to lower levels of serum IgG in patients (Fig. 4C).

#### <sup>169</sup>*The proportion of microbes bound by serum IgG is high in both patients and controls*

170 We next sought to determine how much of the stool microbiome was recognised by serum <sup>171</sup>IgG by measuring the proportion of indigenous stool microbes coated by serum IgG (Fig. 5A 172 and 6B). There was no evidence for any differences in the proportion of stool microbes 173 coated by IgG ('IgG positive') in severe ME/CFS patients compared with controls (Fig. 5C).

## <sup>174</sup>*Characterising the stool microbiome*

175 Using whole metagenome shotgun sequencing the microbial composition of SYBR Green<sup>+</sup> <sup>176</sup>('all') stool microbes isolated by fluorescent activated cell sorting (FACS) was determined <sup>177</sup>(Supplementary Fig. S3). The average number of 'all' microbes collected by FACS was 1.47 178 million. Taxa with a relative abundance greater than  $1 \times 10^{-6}$  were included in downstream 179 analyses and comparisons made at the genus and species level.

180 At the genus level 275 taxa were detected. The 15 most abundant genera across all ME/CFS and matched household control samples (n = 10) were *Bacteroides* (10.4%), *Phocaeicola* (10.1%), *Clostridioides* (9.5%), *Lysobacter* (9.4%), *Faecalibacterium* (8.6%), *Blautia* (7.1%), *Roseburia* (5.8%), *Anaerostipes* (5.5%), *Akkermansia* (4.4%), *Campylobacter* (2.9%), *Agrobacterium* (2.6%), *Methanobrevibacter* (1.9%), *Bifidobacterium*  (1.9%) *Anaerobutyricum* (1.5%) and *Streptococcus* (1.3%) (Supplementary Fig. S3A).

186 At the species level 705 taxa were detected. The 15 most abundant species across all ME/CFS and matched household control samples (n = 10) were *Clostridioides difficile* (9.5%), *Lysobacter enzymogenes* (9.4%), *Faecalibacterium prausnitzii* (8.6%), *Phocaeicola dorei* (6.4%), *Blautia* sp*.* SC05B48 (6.3%), *Anaerostipes hadrus* (5.4%), *Roseburia intestinalis* (4.5%), *Akkermansia muciniphila* (4.3%), *Bacteroides uniformis* (3.7%), *Phocaeicola vulgatus* (3.6%), *Agrobacterium tumefaciens* (2.5%), *Methanobrevibacter* 

<sup>192</sup>*smithii* (1.8%), *Bacteroides cellulosilyticus* (1.6%), *Anaerobutyricum hallii* (1.5%) and

<sup>193</sup>*Campylobacter jejuni* (1.5%) (Supplementary Fig. S3C).

<sup>194</sup>Using three measures of intra-sample diversity, the Shannon index, inverse Simpson 195 index and observed richness, there was no evidence for differences in any of the alpha <sup>196</sup>diversity measures between severe ME/CFS patients and matched household controls at the 197 species level (Supplementary Fig. 4A).

198 Due to the large variation in microbial load in stool samples from severe ME/CFS patients (6.3 x 10<sup>10</sup> cells/gram to 2.6 x 10<sup>11</sup> cells/gram) and controls (1.2 x 10<sup>11</sup> cells/gram to 200 2.0 x  $10^{11}$  cells/gram) (Supplementary Fig. S2), converting relative abundances to absolute 201 abundances increased the heterogeneity amongst samples at both the genus and species levels <sup>202</sup>(Supplementary Fig. S3B and S2D). However, analysis of beta diversity using Bray-Curtis <sup>203</sup>dissimilarity identified subtle changes in both relative microbiome profiles (RMP) and <sup>204</sup>quantitative microbiome profiles (QMP). Samples from patients in pairs three, four and five <sup>205</sup>were most dissimilar to the other samples while samples from patients in pairs one and two 206 clustering together with their matched household controls (Supplementary Fig. S4B).

<sup>207</sup>Functional differences in the microbiome of patients and controls were determined by 208 comparing the abundance of gene families in the 'all' fraction. A total of 464,263 gene <sup>209</sup>families were detected in all participants above the threshold. A further filtering step removed 210 gene families below the threshold in more than seven samples, leaving 84,888 gene families 211 for evaluation. PCA was used to reduce the number of variables by defining principal 212 components (PC) that highlighted the largest sources of variation amongst the samples. PC4 213 identified 11% of variation in functional genes families amongst samples that were 214 attributable to disease status (Supplementary Fig. S5).

# <sup>215</sup>*IgG-Seq identifies antimicrobial signatures unique to each participant*

216 Next, IgG-Seq was used to characterise the indigenous gut microbes bound by serum IgG in 217 severe ME/CFS patients and matched household controls. Briefly, 'IgG positive' and 'IgG 218 negative' microbes were isolated by FACS from bulk stool samples and processed for 219 shotgun metagenomic sequencing to identify taxa preferentially bound by serum IgG (Fig. 6A and 6B). The mean number of 'IgG positive' microbes collected by FACS was  $1.05 \times 10^6$ . 221 The mean number of 'IgG negative' microbes isolated by FACS was  $1.30 \times 10^6$ . Taxa with a 222 relative abundance greater than 1 x  $10^{-5}$  in the 'all' fraction were included in the 'IgG 223 positive' and 'IgG negative' fractions for downstream analyses. Taxonomic comparisons 224 were made at the species level.

225 Observed richness scores were applied to rarefied reads to determine the number of 226 microbial species with serum IgG reactivity (Fig.  $6C$ ). All participants had more than 200 227 species in the 'IgG positive' fraction with a high number of species also identified in the 'IgG 228 negative' fraction. Both patients and controls had a higher mean number of species in their <sup>229</sup>'IgG negative' fraction than their 'IgG positive' fraction (365 vs 339 in patients and 358 vs 230  $322$  in controls). However, most participants had a small number of species ( $\langle 30 \rangle$ ) exclusively 231 in the 'IgG negative' fraction at a relative abundance  $>1 \times 10^{-5}$ , except for the patient from 232 pair three who had 107 species exclusively in their 'IgG negative' fraction (Table 2). In 233 addition, this patient also had a smaller proportion of species recognised by IgG compared 234 with all other participants (Table 2).

235 Next, we assessed the similarity/difference between 'IgG positive' and 'IgG negative' <sup>236</sup>fractions in patients and controls using the Bray-Curtis index and visualising distances using 237 an NMDS plot (Fig. 6D). 'IgG positive' and 'IgG negative' fractions from the same 238 participant shared the greatest similarity. No clustering was seen for either fraction in patients 239 or controls. The 'IgG positive' and 'IgG negative' fractions from patients in pairs three and 240 five were most dissimilar to the other samples.

241 Using the probability ratio developed by Jackson et al., (2021)<sup>25</sup> we scored IgG <sup>242</sup>binding by directly measuring the likelihood of a species being bound by IgG. Positive IgG 243 probability ratios indicate that a species is more likely to be coated with IgG and reside in the <sup>244</sup>'IgG positive' fraction. Conversely, negative IgG probability ratios indicate that a species is <sup>245</sup>more likely to be uncoated and reside in the 'IgG negative' fraction. Probability ratios are not 246 influenced by the relative abundance of a species within the 'all' fraction and therefore 247 measure the quantity of IgG produced against a given species. Of the 423 species detected at 248 a relative abundance greater than  $10^{-5}$ , 101 species were detected in every participant and 249 therefore used in downstream analysis. It is worth noting that despite detecting species falling 250 into the bacteria, fungi, archaea and virus kingdoms, only bacterial species were detected in 251 every participant and consequently used in downstream analysis. Notably, owing to the way 252 in which probability ratios are calculated they tend to be similar across species within 253 participants, with some having consistently lower estimates across all species than others, 254 driven by their overall IgG probability ratio. Probability ratio scores varied amongst species <sup>255</sup>and participants. Each participant had a unique combination of probability ratio scores for 256 different species (Fig. 7). We were unable to meaningfully test for differences in probability 257 ratio scores between patients and controls for individual species due to the small sample size 258 and lack of power to detect significant changes.

259 Finally, we analysed the function of the microbial communities within the 'IgG 260 positive' and 'IgG negative' fractions by analysing the likelihood of a gene family being 261 present in a microbe bound by IgG. IgG probability ratios were calculated for the 1724 gene 262 families that were detected in all participants above the threshold. Using a PCA plot to assess <sup>263</sup>how the ten samples varied with regards to the likelihood of certain gene families being 264 present in microbes bound by IgG (Supplementary Fig. S6), a separation between severe

<sup>265</sup>ME/CFS patients and controls from four households was observed (PC2), corresponding to 266 13% of explained variance.

27.<br>20

#### <sup>268</sup>**Discussion:**

<sup>269</sup>This feasibility study highlights the logistical challenges of including severe, house- or 270 bedbound ME/CFS patients in research studies and collecting biological samples. Contrary to 271 our initial hypothesis, our findings from a small cohort of patients and controls suggests that 272 severe ME/CFS patients may have a reduced serum IgG immune response to stool microbes.

#### <sup>273</sup>*Lessons learnt for the inclusion of severe ME/CFS patients in biomedical research*

274 Despite their significant disability severe ME/CFS patients were enthusiastic and eager to 275 participate in our study with a 58% response rate. However, severe ME/CFS often coincided 276 with additional illness complications that excluded these individuals from the study, 277 hindering recruitment. We also found that symptom severity of house- or bedbound ME/CFS 278 patients fluctuated, making it difficult to arrange home study visits. The wide geographical 279 distribution of participants' homes  $(30 - 140)$  miles from the research institute) restricted 280 sample collection with a minimum of two hours required for sample collection and 281 transportation to the laboratory.

<sup>282</sup>We recruited controls from the same household as the patient to account for environmental confounders of microbiome analyses such as living conditions and diet<sup>26,27</sup>. <sup>284</sup>Previous studies have shown that inclusion of same household controls enables identification 285 of ME/CFS disease-specific microbiome changes<sup>28</sup>. However, the requirement for a matched 286 healthy household control impacted on patient recruitment. Amongst patients not meeting the 287 study eligibility criteria, 44% were excluded due to being unable to identify a matched 288 household control. Considering that household controls were typically carers and parents or

289 spouses of the patient, it was not possible to match age and gender of patients and controls, 290 both of which are confounding variables for immunological<sup>29,30</sup> and microbiome studies<sup>31</sup>. 291 Other confounders potentially discordant amongst patients and controls were BMI, exercise 292 and medications. Our finding of a sparse clustering between results from severe ME/CFS 293 patients and matched household controls suggests that these and perhaps other confounding 294 variables had an influence on immune response to the intestinal microbiome. Future studies 295 should consider including and accounting for as many of these confounding variables in 296 analysis as possible.

# <sup>297</sup>*Severe ME/CFS patients have serum IgG hyporeactivity to stool microbes*

<sup>298</sup>The hypothesis guiding our study was that ME/CFS patients have increased intestinal 299 permeability due to an altered microbiome, which results in translocation of intestinal <sup>300</sup>microbes into the circulation, triggering an immune response. Despite the low study sample 301 size, we found evidence that severe ME/CFS patients in fact have lower serum IgG levels 302 reactive to stool microbes than their matched household controls. This appears to be a 303 property of the patients' immune responses, rather than their microbiome which structurally 304 and functionally closely resembled that of their matched controls. Our findings mirror the 305 findings from pioneering studies investigating immune reactivity to faecal microbes in IBD 306 patients which demonstrated that healthy controls have higher serum IgG reactive to  $\mu$  heterologous stool microbes than to autologous stool microbes<sup>15</sup>. In our study heterologous 308 reactivity was measured using samples from individuals living in the same household which 309 are known to display greater similarity to patients' microbiomes than individuals living in 310. different households<sup>32</sup>. This should increase confidence in identifying microbes that 311 distinguish the microbiome of patients from controls as being a property of the disease. <sup>312</sup>Despite this advantage there were no differences in alpha diversity measures between severe <sup>313</sup>ME/CFS patients and matched household controls at the genus or species level. Instead, our

314 findings provide initial evidence for immune dysfunction in ME patients manifesting as a 315 reduced capacity and reactivity of serum IgG to stool microbes irrespective of their source. 316 Previous studies have described IgG immunodeficiencies in  $ME^{33}$  which could explain why 317 we found reduced levels of serum IgG binding to stool microbes in severe ME/CFS patients. <sup>318</sup>However, there was no evidence of IgG immunodeficiencies in our severe ME/CFS patient 319 cohort. Instead, it may be attributable to IgG antibody repertoires and a less diverse repertoire 320 of antibodies directed at intestinal microbes. The loss of antibody diversity occurs naturally <sup>321</sup>during ageing and is a defining feature of immune senescence and declining immune function  $1322$  in later life<sup>34</sup>. The possibility of premature or accelerated immunosenescence should be a 323 focus of future studies, particularly as it relates to effector immune cells whose functionality 324 is compromised in ME patients, as previously described for NK cells<sup>35</sup>, and here for B cells. <sup>325</sup>An additional possibility relates to immune hibernation in ME/CFS patients which produces a 326 hypometabolic state<sup>36</sup> that may limit lymphocyte responsiveness to foreign antigens and 327 increased tolerance to bacterial endotoxins $37$ .

# <sup>328</sup>*Limitations of the study in addressing the study hypothesis*

329 The severe ME/CFS patients recruited to this pilot study had comorbid IBS, whereas 330 household controls were free of any GI complaints. IBS comorbidity is a confounding 331 variable in ME/CFS microbiome studies as defined microbiome profiles have been described that discriminate between patients with and without IBS comorbidity<sup>9</sup>. To establish whether 333 the results found in this pilot study of severe ME patients are disease specific future studies 334 should compare severe ME/CFS patients with and without comorbid IBS and compare severe <sup>335</sup>ME/CFS patients with comorbid IBS to IBS patients.

<sup>336</sup>We were unable to confirm the presence of increased intestinal permeability within 337 the severe ME/CFS patient cohort. Based upon previous studies most ME patients  $({\sim}67\%)$ 

338 will have increased intestinal permeability compared with healthy controls<sup>13</sup>. An intact 339 intestinal barrier in the severe ME/CFS patients recruited to this study might explain why  $340$  they did not have increased IgG reactivity to autologous stool bacteria compared with their <sup>341</sup>matched healthy household controls. It has been shown that levels of IgG reactive to <sup>342</sup>autologous stool bacteria are elevated in other diseases associated with increased intestinal 343 permeability such as Crohn's disease  $16$ . Future studies should seek to establish the integrity of 344 the intestinal barrier in severe ME/CFS patients.

345 The IgG-Seq protocol used in this research identified serum IgG produced in response 346 to bacteria and fungi. Whilst excluding reactivity to other constituents of the intestinal <sup>347</sup>microbiome in the current study, the method can be adapted to detect IgG reactivity to viruses 348 and archaea that can then be identified and isolated using FACS.

#### <sup>349</sup>*Conclusion*

350 Severe ME patients have historically been excluded from research studies. This pilot study 351 demonstrates the feasibility and challenges associated with including this important and 352 growing population of ME patients in research. In providing evidence of immune dysfunction 353 in severe ME/CFS patients, expressed as hyporesponsive serum IgG responses to intestinal 354 microbes, this study also provides the theoretical and methodological basis and rationale for 355 undertaking more detailed immune function studies in larger cohorts of ME patients.

356

## <sup>357</sup>**Patients and Methods**

#### <sup>358</sup>*Participant recruitment*

359 Ten volunteers were enrolled onto this study between 2018 and 2019: Five severe ME/CFS 360 patients and, as controls, five healthy individuals that were the patients' carers and living in

361 the same household. Severe ME/CFS participants were recruited by the tertiary referral 362 centres Epsom and St Helier University Hospitals (ESTH) CFS Service, Carshalton, UK, and 363 the East Coast Community Healthcare Centre (ECCHC) ME/CFS service, Lowestoft, UK. <sup>364</sup>All severe ME/CFS patients had a confirmed diagnosis of ME/CFS based on a hybrid of the 365 NICE 2007 guidelines<sup>38</sup> and the CDC-1994 criteria<sup>39</sup> and defined as experiencing at least four 366 of the following symptoms for a minimum of 4 months; cognitive difficulties, muscle pain, 367 multi-joint pain, new headaches, recurrent sore throats, cervical/axillary lymphadenopathy, <sup>368</sup>unrefreshing sleep and post exertional malaise. Severity was based on being unable to 369 undertake activities associated with daily living, wheelchair dependency for mobility and 370 being house- or bedbound and requiring aid for washing, using the toilet and eating. All 371 patients were asked to complete the Chalder fatigue questionnaire, shortened medical 372 outcomes study 36-item short form health survey (SF-36), hospital anxiety and depression 373 scale (HADS), a self-efficacy questionnaire, visual analogue pain rating scale and the <sup>374</sup>Epworth sleepiness scale. Matched household controls were defined as individuals who were 375 living with or caring for the severe ME/CFS patient. Matched household controls were 376 excluded if they had a long-term medical condition, in particular gastrointestinal conditions, 377 autoimmune diseases, anxiety, or depression; or were receiving immunomodulatory drugs, 378 statins, beta blockers or steroids. Participants consuming antibiotics or probiotic capsules 379 within the 6 weeks prior to sample collection were excluded.

380 The study was performed in accordance with the Declaration of Helsinki and the 381 International Conference on Harmonisation Good Clinical Practice (ICH GCP) Guideline, 382 and in compliance with national law. The research was approved by the NHS Health <sup>383</sup>Research Authority London Hampstead Research Ethics Committee (REC 17/LO/1102, <sup>384</sup>IRAS ID 218545). This study was registered on the clinicaltrials.gov database <sup>385</sup>(NCT03254823). All participants provided fully informed written consent. The collection,

386 storage and use of human tissue samples was carried out within the terms of the Human 387 Tissue Act 2004 (Human Tissue Authority).

#### <sup>388</sup>*Sample collection and processing*

<sup>389</sup>Fresh stool and blood samples were collected from each participant within a 24 h window 390 during a home visit. Twenty millilitres of blood were collected in serum separator tubes (BD <sup>391</sup>Vacutainer). Serum was separated from whole blood following the manufacturers protocol 392 and immediately stored at  $-80^{\circ}$ C. Stool samples were collected immediately after defecation 393 in a Fecotainer® (AT Medical BV) with an Oxoid™ AnaeroGen<sup>™</sup> compact sachet (Thermo 394 Scientific) to preserve anaerobic bacteria. The consistency and appearance of fresh stool samples was recorded using the Bristol stool form scale  $(BSFS)$ <sup>40</sup>. Stool samples were stored 396 at  $4^{\circ}$ C for <24 h. Following homogenisation aliquots of the bulk homogenate and of 40% 397 stool microbial glycerol suspensions were stored at -80°C. Glycerol stocks were prepared by 398 diluting stool samples  $(10\% \t w/v)$  with PBS, collecting the supernatant following separate sentrifugation at 300g for 5 min at  $20^{\circ}$ C and diluted 1:1 with 80% v/v glycerol.

## <sup>400</sup>*Stool water content*

401 Non-diluted aliquots of stool were weighed before and after freeze drying using the 402 ModulyoD freeze dryer (Thermo Electron Corp.) for 12 h. Water content was calculated 403 using the following equation.

$$
\frac{(wet \; weight - dry \; weight)}{wet \; weight} \times 100
$$

#### <sup>404</sup>*Stool microbial load*

405 Non-diluted stool aliquots were thawed on ice and diluted  $(1\% \t w/v)$  with PBS solution 406 containing 0.1% w/v BSA fraction V. Samples were homogenised using a Kimble™ 407 Kontes™ Pellet Pestle™ Cordless motor and filtered through a 70 µm cell strainer. Filtered

408 microbial suspensions were diluted 1:1600, 1:3200 and 1:6400; then 200 $\mu$ l of each dilution 409 were incubated with 10µl of 1:100 SYBR™ Green I nucleic acid gel stain (Thermofischer 410 Scientific) for 30 min. Microbial load was determined using the Guava® easyCyte™ 5HT 411 equipped with a 488 nm laser. Prior to sample acquisition the instrument was cleaned 412 following manufacturers' instructions and calibrated using the Guava® easyCheck™ kit. 413 Stool microbes (SYBR Green+ events) were enumerated using Guava® Suite Software v3.3.

## <sup>414</sup>*Stool IgA concentration*

415 Non-diluted stool aliquots were thawed on ice, diluted (10% w/v) with 0.2M NaHCO<sub>3</sub>, pH 416 9.4 and homogenised using a Kimble™ Kontes™ Pellet Pestle™ Cordless motor. Samples 417 were centrifuged twice at  $16,000g$  for 5 min at  $20^{\circ}$ C and after both rounds of centrifugation 418 the pellet and supernatant were separated. The supernatants were pooled and used to analyse <sup>419</sup>free secretory IgA (sIgA) by ELISA. The pellet was washed and resuspended to the original 420 volume and used to analyse microbe associated/bound sIgA by ELISA. All reactants except 421 for the blocking solution and wash buffers were added in volumes of 100  $\mu$ l/well. All washes 422 were repeated three times with PBS and  $0.05\%$  Tween<sup>TM</sup> 20 unless otherwise stated. Nunc 423 MaxiSorp™ flat-bottom plates (Thermo Fisher Scientific) were coated for 16h at 4<sup>°</sup>C with <sup>424</sup>10-fold serial dilutions (1 to 1:1000000) of samples and with 2-fold serial dilutions (250-3.9 425 ng/ml) of a human colostrum IgA standard (Sigma), diluted with 0.2M NaHCO<sub>3</sub>, pH 9.4. 426 Samples and standards were plated in duplicate. Plates were washed and then blocked for 3h 427 with 300µl/well of PBS, 0.05% Tween<sup>TM</sup> 20, 2% BSA fraction V, 1% normal mouse serum <sup>428</sup>(Thermo Fisher Scientific). Plates were washed and then incubated with 1000 ng/ml biotin 429 conjugated mouse anti-human IgA1/IgA2 monoclonal antibody (Pharmingen) diluted in PBS, 430 0.05% Tween<sup>™</sup> 20, 2% BSA fraction V, 1% normal mouse serum. After 1h of incubation at 431  $20^{\circ}$ C plates were washed and incubated with 1:80000 HRP-Conjugated Streptavidin (Thermo 432 Fisher Scientific) diluted in PBS, 0.05% Tween<sup>™</sup> 20, 2% BSA fraction V, 1% normal mouse



#### <sup>437</sup>*Serum IgG quantification*

<sup>438</sup>Total serum IgG was measured using the commercial Invitrogen ELISA kit (Thermo Fisher 439 Scientific). Samples were measured in duplicate.

#### <sup>440</sup>*Serum IgG levels to autologous and heterologous stool microbes*

<sup>441</sup>Glycerol stocks of stool microbes were thawed and washed three times with PBS at 8000g for 442  $\,$  5 min at 20 $\,^{\circ}$ C. The pellet was resuspended in 1ml PBS. Serial dilutions (2-fold) of stool 443 microbes in PBS were plated in duplicate in a 96-well flat bottom Corning™ Costar™ 9018 444 plate. Absorbances were read at 570 nm and stool microbes were resuspended to an optical 445 density of 0.05 with 0.1M NaHCO<sub>3</sub>, pH 9.4.

<sup>446</sup>Serum IgG reactivity to autologous ('self') or heterologous ('non-self', matched 447 patient or control) stool microbes was measured by ELISA. All washes were repeated three 448 times with 200  $\mu$ l/well PBS and 0.1% Tween<sup>TM</sup> 20 unless otherwise stated. Nunc 449 MaxiSorp<sup>™</sup> flat-bottom plates (Thermo Fisher Scientific) were coated for 16h at  $4^{\circ}$ C with <sup>450</sup>100 µl/well of stool microbes. Plates were washed and then blocked for 3h at room 451 temperature under agitation with PBS, 2% BSA fraction V, 1% normal goat serum (Sigma-452 Aldrich). Plates were incubated for 1 h at  $20^{\circ}$ C with 50 µl/well of complement inactivated <sup>453</sup>serum samples 2-fold serially diluted (1:80-1:320) in PBS, 2% BSA fraction V, 1% normal <sup>454</sup>goat serum. Plates were washed and incubated for 1h at room temperature under agitation 455 with 100  $\mu$ /well of 1:500 goat anti-human IgG H&L (HRP) (Abcam,) diluted in PBS, 2% 456 BSA fraction V, 1% normal goat serum. Plates were washed six times and incubated with



# <sup>460</sup>*Microbial flow cytometry*

461 Systemic IgG and faecal IgA binding to stool microbes was assessed by microbial flow 462 cytometry. All buffers were filter sterilised using a 0.22-um filter before use. Aliquots of <sup>463</sup>non-diluted stool samples were processed and the microbial concentration in each stool 464 sample measured as described earlier. Microbes were resuspended to 2 x  $10^6$  cells/ml in PBS 465 with 0.1% BSA. 500µl of complement inactivated serum was diluted 1:100 in PBS with 0.1% 466 BSA and incubated for 30 min at  $20^{\circ}$ C with 200 µl of 1 x  $10^{\circ}$  cells/ml of stool microbes. For 467 secretory IgA measurements stool microbes were not incubated with serum. Samples were 468 washed in PBS with 0.1% BSA (5 min,  $1.2 \times 10^4$  rpm) and microbes were resuspended to 1 x  $10^6$  cells/ml and incubated with 1:1000 SYBR<sup>™</sup> Green I nucleic acid gel stain and 1:100 470 secondary conjugated antibodies (anti-human IgA-APC (Miltenyi Biotec) and anti-human <sup>471</sup>IgG-APC/Cy7 (BioLegend) or their respective isotype controls. Samples were fixed with 472 0.75% v/v paraformaldehyde. Acquisition of cellular events was performed using the BD <sup>473</sup>LSRFortessa™ (BD Biosciences) and analysed using FlowJo™ software. Frequencies of <sup>474</sup>antibody bound stool microbes were expressed as percentages. The percentage of Ig-bound 475 microbes was normalised by subtracting frequency of Ig-bound microbes measured using 476 isotype controls.

# <sup>477</sup>*Metagenomic shotgun sequencing analysis of total gut microbiota and IgG-coated*  <sup>478</sup>*microbes (IgG-Seq)*

<sup>479</sup>*Microbial cell sorting*

480 Non-diluted stool samples were processed and stained for IgG flow cytometry analysis as 481 described previously. Isotype controls were not used in microbial cell sorting. Microbes were 482 diluted to 1 x  $10^7$  cells/ml and cell sorting achieved using the Sony SH800S cell sorter 483 equipped with four lasers: 488 nm, 405nm, 638nm and 651nm. Prior to sample acquisition 484 the instrument was cleaned and calibrated according to the manufacturer's instructions. 485 Microbes (1 x 10<sup>6</sup>) were collected from the following three fractions: 1) 'all' (SYBR<sup>+</sup> 486 microbes), 2) 'IgG positive' (SYBR<sup>+</sup>IgG<sup>+</sup>), 3) 'IgG negative' (SYBR<sup>+</sup>IgG<sup>-</sup>). Fractions were 487 centrifuged and immediately stored at  $-20^{\circ}$ C as dry pellets.

# <sup>488</sup>*DNA extraction, processing and sequencing*

489 DNA was extracted using the Gram-positive bacteria genomic DNA purification protocol 490 from the GeneJET DNA genomic DNA purification kit (Thermoscientific) with the following 491 modifications: 1) 0.52 kU/ml achromopeptidase was added to the lysis buffer and the 492 incubation time increased to 60 min; 2) incubation with lysis solution and proteinase K was 493 increased to 50 min. DNA was precipitated using 0.7X solid phase reversible immobilisation <sup>494</sup>bead clean-up with KAPA pure beads (Roche). Whole genome amplification was performed 495 using the REPLI-g advanced DNA single cell kit (QIAGEN). The quality and quantity of 496 amplified genomic DNA were determined using the Agilent Tapestation 4200 and the 497 Quanti-iT™ dsDNA high sensitivity assay kit (Thermo Fisher Scientific). A ready-to-load 498 pooled sequencing library was prepared by the in-house QIB sequencing service using the 499 Illumina DNA prep kit (Illumina, 20018704) and the KAP2G Robust PCR kit (Sigma), 500 followed by sequencing using  $2 \times 150$  bp paired-end chemistry (PE150) on the Illumina 501 NovaSeq 6000 platform (Novogene Ltd., UK).

<sup>502</sup>Paired-end sequencing reads were provided as FASTQ format. All raw sequencing 503 reads were pre-processed using tools retrieved from the BioConda repository<sup>41</sup>. SeqFu

504 (v1.8.5)<sup>42</sup> was used to assess the quality of raw sequencing reads and those bases below 505 Phred quality score of 15 were removed using Fastp (v0.20.0)<sup>43</sup>. Human genomic DNA 506 identified by Kraken $2^{44}$  against the Genome Reference Consortium Human Build 37 <sup>507</sup>(GRCh37/hg19) database were removed. Taxonomic assignment of remaining sequencing 508 reads was done using Kraken $2^{44}$  against the 'PlusPF' database containing archaea, bacteria, 509 viral, plasma, human1, UniVec\_Core, Protozoa and Fungi 510 https://benlangmead.github.io/aws-indexes/k2. Abundance of reads at the species level was 511 estimated using Bracken<sup>45</sup>. Taxonomic read counts were converted to relative abundances by 512 total sum scaling to 1.

# <sup>513</sup>*Relative and quantitative microbiome profiling*

<sup>514</sup>The 'all' fraction from microbial cell sorting was used for relative microbiome profiling 515 (RMP) and quantitative microbiome profiling (QMP). The cut off threshold of 1 x  $10^{-6}$  was 516 applied to relative abundances and a pseudocount of 1 x  $10^{-7}$  was added. The microbial load 517 of each species was calculated on these modified relative abundances using the equation 518 below.

absolute abundance (cells/g)
$$
_{ij} = RA_{ij} \times total cell concentration (cells/g) $_{j}$
$$

#### <sup>519</sup>*Analysing IgG binding of taxa*

520 RMP data was used for IgG binding analysis with a cut off threshold of 1 x  $10^{-5}$ . In addition, 521 for each participant if a species was not detected in the 'all' fraction above the threshold then 522 this species was subsequently removed from respective 'IgG positive' and 'IgG negative' 523 fractions. The 'IgAScores' (v.0.1.2)<sup>25</sup> R package was used to calculate IgG probability ratios 524 using the 'igascores' function with method set to 'probratio', pseudocount 'c' set to 1 x  $10^{-5}$ 525 and 'scaleratio' set to TRUE.

$$
probability\;ratio_{ij}\;=log2\left(\frac{\left(lgG_{ij}^{+}\times\;Fraction\;size_{j}^{lgG+}\right)+c}{\left(lgG_{ij}^{-}\times\;Fraction\;size_{j}^{lgG-}\right)+c}\right)
$$

## <sup>526</sup>*Alpha diversity*

527 The diversity function from the 'vegan' R package (v.2.5-7)<sup>46</sup> was used to calculate Shannon 528 indices and inverse Simpson indices. The rarefy function from 'vegan' (v.2.5-7)<sup>46</sup> was used 529 to rarefy reads to the lowest sequencing depth. Observed species' richness was the number of 530 species remaining following rarefaction.

<sup>531</sup>*Beta diversity* 

532 The vegdist function from 'vegan' (v.2.5-7)<sup>46</sup> was used to calculate Bray-Curtis indices on 533 relative abundances. The metMDS function from 'vegan'  $(v.2.5-7)^{46}$  was used to performed 534 non-metric multidimensional scaling (NDMS) on Bray-Curtis indices.

#### <sup>535</sup>*Functional analysis*

536 Gene families were identified using the HMP Unified Metabolic Analysis Network 3.0 537 (HUMAnN 3.0) package from the bioBakery suite<sup>47,48</sup>. In all participants each gene family <sup>538</sup>was filtered by the following criteria: if a gene family was not present in the 'all' fraction the 539 reads per kilobase (RPK) were zeroed in the 'IgG positive' and 'IgG negative' fractions of 540 that participant. The humann\_renorm\_table utility script from HUMAnN 3.0 was used to 541 convert gene families from RPK to relative abundances. Community level classifications of 542 gene families were used in downstream analysis. A cut off threshold of 1 x  $10^{-6}$  was applied 543 to all samples.

544 To analyse gene families in the microbiome of severe ME/CFS patients compared <sup>545</sup>with household controls the 'all' fraction was used. Gene families that were below the 546 threshold in seven or more samples were discarded from downstream analysis. The clr

547 function from the 'compositions' R package (v 2.0-4)<sup>49</sup> was used to CLR transform the 548 relative abundance of gene families. The pca function from the 'mixOmics' R package (v 549 6.18.1)<sup>50</sup> was used to perform principal component analysis (PCA) on gene families. Severe <sup>550</sup>ME/CFS patients and their matched household controls were not treated as paired samples in 551 this analysis.

552 To analyse gene families of IgG reactive microbes IgG probability ratios were 553 calculated using the relative abundance of gene families in the 'IgG positive' fraction and the  $1554$  'IgG negative' fraction as described earlier, with a pseudocount set to 6 x  $10$ . Gene families 555 that did not have IgG probability ratios in all samples were discarded from downstream 556 analysis. PCA was then performed as described previously.

#### <sup>557</sup>*Statistical analysis*

<sup>558</sup>Statistical analyses and graphical representations were performed in R using the following 559 packages: 'ggplot2' (v3.4.0)<sup>51</sup>, 'reshape2' (v1.4.4)<sup>52</sup>, 'data.table' (v1.14)<sup>53</sup>, 'dplyr' (v1.1.0) 560  $\frac{54}{7}$ , 'ggpubr' (V0.5.0)<sup>55</sup>. Graphs were also made using GraphPad Prism 5.04. Prior to analysis 561 data were log-transformed if there was evidence for non-normality. Pairwise comparisons 562 between severe ME/CFS patients and their matched household controls were done using a 563 two-tailed paired *t*-test. Correlations were assessed with Pearson (*r*) correlation test.

# <sup>564</sup>*Common data elements for ME research*

- <sup>565</sup>This study used the National Institute of Neurological Disorders and Stroke Common Data
- <sup>566</sup>Elements guidelines' for reporting microbiome/microorganisms biomarkers in ME/CFS
- 567 research (http://www.commondataelements.ninds.nih.gov/)<sup>56</sup>.

## <sup>568</sup>**Acknowledgements**



- <sup>581</sup>**Declaration of interest statement**
- 582 The authors report there are no competing interests to declare.
- <sup>583</sup>**Data availability statement**
- 584 The raw WMS data are available at the European Nucleotide Archive under study accession
- 585 PRJEB61661. (http://www.ebi.ac.uk/ena/broswer/view/PRJEB61661).

## **References**

- 587 1 Lim EJ, Son CG. Review of case definitions for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). J. Transl. Med. 2020;18:289. doi: 10.1186/s12967-020- 589 02455-0. PMID: 32727489.
- 2 Pendergrast T, Brown A, Sunnquist M, Jantke R, Newton JL, Strand EB, Jason LA. 591 Housebound versus nonhousebound patients with myalgic encephalomyelitis and 592 chronic fatigue syndrome. Chronic Illn. 2016;12:292-307. doi: 10.1177/1742395316644770. PMID: 27127189.
- 3 Chu L, Valencia IJ, Garvert DW, Montoya, JG. Onset Patterns and Course of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Front Pediatr. 2019;7:12. doi: 596 10.3389/fped.2019.00012. PMID: 30805319.
- 4 Lim EJ, Ahn YC, Jang ES, Lee SW, Lee SH, Son CG. Systematic review and meta-analysis of the prevalence of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME). J. Transl. Med. 2020;18:100. doi: 10.1186/s12967-020-02269-0. PMID: 32093722.
- 5 Salari N, Khodayari Y, Hosseinian-Far A, Zarei H, Rasoulpoor S, Akbari H, Mohammadi M. Global prevalence of chronic fatigue syndrome among long COVID-19 patients: A systematic review and meta-analysis. Biopsychosoc. Med. 2022;16:21. 604 doi: 10.1186/s13030-022-00250-5. PMID: 36274177.
- 6 Missailidis D, Annesley SJ, Fisher, PR. Pathological Mechanisms Underlying Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Diagnostics (Basel). 2019;9:80. doi: 10.3390/diagnostics9030080. PMID: 31330791.
- 7 Aaron LA, Burke MM, Buchwald D. Overlapping conditions among patients with chronic fatigue syndrome, fibromyalgia, and temporomandibular disorder. Arch. 610 Intern. Med. 2000;160:221-227. doi: 10.1001/archinte.160.2.221. PMID: 10647761.

- <sup>611</sup>8 Giloteaux L, Goodrich JK, Walters WA, Levine SM, Ley RE, Hanson MR. Reduced
- 612 diversity and altered composition of the gut microbiome in individuals with myalgic <sup>613</sup>encephalomyelitis/chronic fatigue syndrome. Microbiome. 2016;4:30. doi:
- <sup>614</sup>10.1186/s40168-016-0171-4. PMID: 27338587.
- <sup>615</sup>9 Nagy-Szakal D, Williams BL, Mishra N, Che X, Lee B, Bateman L, Klimas NG, 616 Komaroff AL, Levine S, Montoya JG, et al. Fecal metagenomic profiles in subgroups
- 617 of patients with myalgic encephalomyelitis/chronic fatigue syndrome. Microbiome. <sup>618</sup>2017;5:44. doi: 10.1186/s40168-017-0261-y. PMID: 28441964.
- <sup>619</sup>10 Armstrong CW, McGregor NR, Lewis DP, Butt HL, Gooley PR. The association of 620 fecal microbiota and fecal, blood serum and urine metabolites in myalgic 621 encephalomyelitis/chronic fatigue syndrome. Metabolomics. 2016;13:8. doi: 622 10.1007/s11306-016-1145-z.
- <sup>623</sup>11 Xiong R, Gunter C, Fleming E, Vernon SD, Bateman L, Unutma*.* Multi-'omics of gut <sup>624</sup>microbiome-host interactions in short- and long-term myalgic <sup>625</sup>encephalomyelitis/chronic fatigue syndrome patients. Cell Host Microbe. <sup>626</sup>2023;31:273-287.e275. doi: 10.1016/j.chom.2023.01.001. PMID: 36758521.
- <sup>627</sup>12 Guo C, Che X, Briese T, Ranjan A, Allicock O, Yates RA, Cheng A, March D, 628 Hornig M, Komaroff AL et al. Deficient butyrate-producing capacity in the gut <sup>629</sup>microbiome is associated with bacterial network disturbances and fatigue symptoms 630 in ME/CFS. Cell Host Microbe. 2023;31:288-304.e288. doi: <sup>631</sup>10.1016/j.chom.2023.01.004. PMID: 36758522.
- <sup>632</sup>13 Maes M, Mihaylova I, Leunis JC. Increased serum IgA and IgM against LPS of <sup>633</sup>enterobacteria in chronic fatigue syndrome (CFS): indication for the involvement of 634 gram-negative enterobacteria in the etiology of CFS and for the presence of an

- increased gut-intestinal permeability. J. Affect. Disord. 2007;99:237-240. doi: 10.1016/j.jad.2006.08.021. PMID: 17007934.
- 14 Shukla SK, Cook D, Meyer J, Vernon SD, Le T, Clevidence D, Robertson CE, 638 Schrodi SJ, Yale S, Frank DN. Changes in Gut and Plasma Microbiome following Exercise Challenge in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). PLoS One. 2015;**10**:e0145453. doi: 10.1371/journal.pone.0145453. 641 PMID: 26683192.
- 15 Duchmann R, Neurath MF, Meyer zum Büschenfelde KH. Responses to self and non-self intestinal microflora in health and inflammatory bowel disease. Res. Immunol*.* 1997;148:589-594. doi: 10.1016/s0923-2494(98)80154-5. PMID: 9588839.
- 16 Harmsen HJ, Pouwels SD, Funke A, Bos NA, Dijkstra G. Crohn's disease patients have more IgG-binding fecal bacteria than controls. Clin. Vaccine Immunol. 2012;19:515-521. doi:10.1128/cvi.05517-11. PMID: 22336288.
- 17 Ruff WE, Greiling TM, Kriegel MA. Host-microbiota interactions in immune-mediated diseases. Nat. Rev. Microbiol. 2020;18:521-538. doi: 10.1038/s41579-020- 650 0367-2. PMID: 32457482.
- 651 18 Maes M, Ringel K, Kubera M, Anderson G, Morris G, Galecki P, Geffard M. In myalgic encephalomyelitis/chronic fatigue syndrome, increased autoimmune activity against 5-HT is associated with immuno-inflammatory pathways and bacterial translocation. J. Affect. Disord. 2013;150:223-230. doi: 10.1016/j.jad.2013.03.029. 655 PMID: 23664637.
- 19 Quigley EMM. Gut bacteria in health and disease. Gastroenterol Hepatol (N Y). 2013;9:560-569. PMID: 24729765.

- 20 Keyt BA, Baliga R, Sinclair AM, Carroll SF, Peterson MS. Structure, Function, and
- Therapeutic Use of IgM Antibodies. Antibodies (Basel). 2020;9:53. doi: 10.3390/antib9040053. PMID: 33066119.
- 21 de Sousa-Pereira P, Woof JM. IgA: Structure, Function, and Developability. Antibodies (Basel). 2019;8:57. doi: 10.3390/antib8040057. PMID: 31817406.
- 22 Vogl T, Kalka IN, Klompus S, Leviatan S, Weinberger A, Segal E. Systemic antibody responses against human microbiota flagellins are overrepresented in chronic fatigue syndrome patients. Sci Adv. 2022;8:eabq2422. doi: 10.1126/sciadv.abq2422. PMID: 666 36149952.
- 23 Vogl T, Klompus S, Leviatan S, Kalka IN, Weinberger A, Wijmenga C, Fu J, Zhernakova A, Weersma RK, Segal E. Population-wide diversity and stability of serum antibody epitope repertoires against human microbiota. Nat. Med. 2021;27:1442-1450. doi: 10.1038/s41591-021-01409-3. PMID: 34282338.
- 24 Palm NW, de Zoete MR, Cullen TW, Barry NA, Stefanowski J, Hao L, Degnan PH, 672 Hu J, Peter I, Zhang W, et al. Immunoglobulin A coating identifies colitogenic bacteria in inflammatory bowel disease. Cell. 2014;158:1000-1010. doi: 10.1016/j.cell.2014.08.006. PMID: 25171403.
- 25 Jackson MA, Pearson C, Ilott NE, Huus KE, Hegazy AN, Webber J, Finlay BB, 676 Macpherson AJ, Powrie F, Lam LH. Accurate identification and quantification of commensal microbiota bound by host immunoglobulins. Microbiome**.** 2021;9:33. 678 doi: 10.1186/s40168-020-00992-w. PMID: 33516266.
- 26 Redondo-Useros N, Nova E, González-Zancada N, Díaz LE, Gómez-Martínez S, Marcos A. Microbiota and Lifestyle: A Special Focus on Diet. Nutrients**.**  2020;12:1776. doi: 10.3390/nu12061776. PMID: 32549225.

- 682 27 Gacesa R, Kurilshikov A, Vich Vila A, Sinha T, Klaassen MAY, Bolte LA, Andreu-
- 683 Sánchez S, Chen L, Collij V, Hu S et al. Environmental factors shaping the gut
- <sup>684</sup>microbiome in a Dutch population. Nature**.** 2022;604:732-739. doi:10.1038/s41586-
- 685 022-04567-7. PMID: 35418674.
- <sup>686</sup>28 Lupo GFD, Rocchetti G, Lucini L, Lorusso L, Manara E, Bertelli M, Puglisi E, <sup>687</sup>Capelli E. Potential role of microbiome in Chronic Fatigue Syndrome/Myalgic <sup>688</sup>Encephalomyelits (CFS/ME). Sci. Rep. 2021;11:7043. doi: 10.1038/s41598-021- 689 86425-6. PMID: 33782445.
- <sup>690</sup>29 Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol. <sup>691</sup>2016;16**:**626-638. doi:10.1038/nri.2016.90. PMID: 27546235.
- <sup>692</sup>30 Milan-Mattos JC, Anibal FF, Perseguini NM, Minatel V, Rehder-Santos P, Castro <sup>693</sup>CA, Vasilceac FA, Mattiello SM, Faccioli LH, Catai AM. Effects of natural aging and <sup>694</sup>gender on pro-inflammatory markers. Braz J Med Biol Res. 2019;52:e8392. doi: 695 10.1590/1414-431x20198392. PMID: 31411315.
- <sup>696</sup>31 Vujkovic-Cvijin I, Sklar J, Jiang L, Natarajan L, Knight R, Belkaid Y. Host variables <sup>697</sup>confound gut microbiota studies of human disease. Nature**.** 2020;587:448-454. doi: <sup>698</sup>10.1038/s41586-020-2881-9. PMID: 33149306.
- <sup>699</sup>32 Lax S, Smith DP, Hampton-Marcell J, Owens SM, Handley KM, Scott NM, Gibbons <sup>700</sup>SM, Larsen P, Shogan BD, Weiss S, et al*.* Longitudinal analysis of microbial 701 interaction between humans and the indoor environment. Science. 2014:345:1048-702 1052. doi: 10.1126/science.1254529. PMID: 25170151.
- <sup>703</sup>33 Guenther S, Loebel M, Mooslechner AA, Knops M, Hanitsch LG, Grabowski P, 704 Wittke K, Meisel C, Unterwalder N, Volk HD, et al. Frequent IgG subclass and 705 mannose binding lectin deficiency in patients with chronic fatigue syndrome. Hum. 706 Immunol. 2015;76:729-735. doi: 10.1016/j.humimm.2015.09.028. PMID: 26429318.

- <sup>707</sup>34 Aiello A, Farzaneh F, Candore G, Caruso C, Davinelli S, Gambino CM, Ligotti ME,
- <sup>708</sup>Zareian N, Accardi G. Immunosenescence and Its Hallmarks: How to Oppose Aging 709 Strategically? A Review of Potential Options for Therapeutic Intervention. Front. 710 Immunol. 2019;10:2247. doi: 10.3389/fimmu.2019.02247. PMID: 31608061.
- <sup>711</sup>35 Eaton-Fitch N, du Preez S, Cabanas H, Staines D, Marshall-Gradisnik S. A systematic 712 review of natural killer cells profile and cytotoxic function in myalgic 713 encephalomyelitis/chronic fatigue syndrome. Syst Rev. 2019;8:279. 714 doi:10.1186/s13643-019-1202-6. PMID: 31727160.
- <sup>715</sup>36 Naviaux RK, Naviaux JC, Li K, Bright AT, Alaynick WA, Wang L, Baxter A, Nathan 716 N, Anderson W, Gordon E. Metabolic features of chronic fatigue syndrome. Proc. 717 Natl. Acad. Sci. U. S. A. 2016;113**:E5472-5480**. doi: 10.1073/pnas.1607571113. 718 PMID: 27573827.
- <sup>719</sup>37 Morris G, Maes M, Berk M, Puri BK. Myalgic encephalomyelitis or chronic fatigue 720 syndrome: how could the illness develop? Metab. Brain Dis. 2019;34:385-415. doi: 721 10.1007/s11011-019-0388-6. PMID: 30758706.
- <sup>722</sup>38 Baker R, Shaw EJ. Diagnosis and management of chronic fatigue syndrome or 723 myalgic encephalomyelitis (or encephalopathy): summary of NICE guidance. BMJ. <sup>724</sup>2007;335:446-448. doi: 10.1136/bmj.39302.509005.AE. PMID: 17762037.
- <sup>725</sup>39 Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, Komaroff A. The chronic <sup>726</sup>fatigue syndrome: a comprehensive approach to its definition and study. International 727 Chronic Fatigue Syndrome Study Group. Ann Intern Med. 1994;121:953-9. doi: <sup>728</sup>10.7326/0003-4819-121-12-199412150-00009. PMID: 7978722.
- <sup>729</sup>40 Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. 730 Scand J Gastroenterol. 1997;32:920-4. doi: 10.3109/00365529709011203. PMID: 731 9299672.

- <sup>732</sup>41 Grüning B, Dale R, Sjödin A, Chapman BA, Rowe J, Tomkins-Tinch CH, Valieris R,
- <sup>733</sup>Köster J; Bioconda Team. Bioconda: sustainable and comprehensive software 734 distribution for the life sciences. Nat Methods. 2018;15:475-476. doi: 735 10.1038/s41592-018-0046-7. PMID: 29967506.
- <sup>736</sup>42 Telatin A, Fariselli P, Birolo G. SeqFu: A Suite of Utilities for the Robust and 737 Reproducible Manipulation of Sequence Files. Bioengineering (Basel). 2021;8:59. 738 doi: 10.3390/bioengineering8050059. PMID: 34066939.
- <sup>739</sup>43 Chen S, Zhou Y, Chen Y, Gu J. fastp: an ultra-fast all-in-one FASTQ preprocessor. 740 Bioinformatics. 2018;34:i884-i890. doi: 10.1093/bioinformatics/bty560. PMID: 741 30423086.
- <sup>742</sup>44 Wood DE, Lu J, Langmead B. Improved metagenomic analysis with Kraken 2. <sup>743</sup>Genome Biol. 2019;20:257. doi: 10.1186/s13059-019-1891-0. PMID: 31779668.
- <sup>744</sup>45 Lu J, Breitwieser FP, Thielen P, Salzberg SL. Bracken: estimating species abundance 745 in metagenomics data. PeerJ Computer Science. 2017;3:e104. doi: 10.7717/peerj-746 cs.104
- <sup>747</sup>46 Oksanen J, Simpson GL, Blanchet FG, Kindt R, Legendre P, Minchin PR, O'Hara 748 RB, Solymos P, Stevens MHH, Szoecs E, et al. \_vegan: Community Ecology 749 Package<sub>-</sub>. R package version v.2.6-4. 2022. < https://CRAN.R-750 project.org/package=vegan>.
- <sup>751</sup>47 Beghini F, McIver LJ, Blanco-Míguez A, Dubois L, Asnicar F, Maharjan S, Mailyan 752 A, Manghi P, Scholz M, Thomas AM, et al. Integrating taxonomic, functional, and <sup>753</sup>strain-level profiling of diverse microbial communities with bioBakery 3. Elife. <sup>754</sup>2021;10:e65088. doi: 10.7554/eLife.65088. PMID: 33944776.

- <sup>755</sup>48 McIver LJ, Abu-Ali G, Franzosa EA, Schwager R, Morgan XC, Waldron L, Segata N,
- 756 Huttenhower C. bioBakery: a meta'omic analysis environment. Bioinformatics.
- <sup>757</sup>2018;34:1235-1237. doi: 10.1093/bioinformatics/btx754. PMID: 29194469.
- <sup>758</sup>49 van den Boogaart KG, Tolosana-Delgado R, Bren M. \_compositions: Compositional
- 759 Data Analysis<sub>\_</sub>. R package version 2.0-6. 2023. <https://CRAN.R-760 project.org/package=compositions>.
- 761 50 Rohart F, Gautier B, Singh A, Lê Cao KA. mixOmics: An R package for 'omics 762 feature selection and multiple data integration. PLoS Comput Biol. <sup>763</sup>2017;13:e1005752. doi: 10.1371/journal.pcbi.1005752. PMID: 29099853.
- 764 51 Wickham, H. ggplot2: Elegant Graphics for Data Analysis. New York: Springer-765 Verlag; 2016.
- <sup>766</sup>52 Wickham, H. Reshaping Data with the reshape Package. J Stat Soft. 2007;**21**:1-20. 767 doi: 10.18637/jss.v021.i12.
- 768 53 Dowle M, Srinivasan A. \_data.table: Extension of `data.frame`\_. R package version 769 1.14.6. 2022. <https://CRAN.R-project.org/package=data.table>.
- <sup>770</sup>54 Wickham H, François R, Henry L, Müller K, Vaughan D. \_dplyr: A Grammar of Data
- 771 Manipulation\_. R package version 1.1.0. 2023. <https://CRAN.R-772 project.org/package=dplyr>.
- <sup>773</sup>55 Alboukadel K. \_ggpubr: 'ggplot2' Based Publication Ready Plots\_. R package version  $774$  0.6.0. 2023.  $\frac{\text{https://CRAN.R-project.org/package=ggpubr}}{174}$ .
- <sup>775</sup>56 Grinnon ST, Miller K, Marler JR, Lu Y, Stout A, Odenkirchen J, Kunitz S. National
- 776 Institute of Neurological Disorders and Stroke Common Data Element Project z77 approach and methods. Clin Trials. 2012;9:322-329. doi:
- <sup>778</sup>10.1177/1740774512438980. PMID: 22371630.

# 780 Table 1. Severe ME/CFS clinical characteristics





\* questionnaire completed by 4 patients

\*\* questionnaire completed by 3 patients

\*\*\* questionnaire completed by 2 patients

781

782



# 783 Table 2. Proportion of species detected that are recognised by serum IgG

# 786 SUPPLEMENTARY TABLE 1. The size of IgG positive and IgG negative fractions

787 collected during IgG-Seq. This data was used to calculation of IgG probability ratio scores.



789

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.05.21.23290299;](https://doi.org/10.1101/2023.05.21.23290299) this version posted May 23, 2023. The copyright holder for this preprint



- 797 (n=5) and matched household controls (n=5) for (A) microbe bound IgA, and (B) microbe
- 798 non-bound IgA. For both plots *p values* were calculated using a two-tailed paired *t*-test.

800 FIGURE 3. Profiling stool IgA. (A) Overview of sample preparation for IgA-bound microbe

801 fluorescent activated cell sorting (FACS) analysis. (B) Representative flow cytometric

802 analysis of IgA-bound stool microbes. (C) Proportion of stool microbes bound by IgA in

803 severe ME/CFS patients (n=5) and matched household controls (n=5). P values were

804 calculated using a two-tailed paired t-test. (D) Analysis of IgA-bound microbial load in

805 severe ME/CFS patients (n=5) and matched household controls (n=5). P values were

806 calculated using a two-tailed paired t-test.

807

<sup>808</sup>FIGURE 4. Serum IgG reactivity to autologous and heterologous stool microbes. (A)

809 Overview of assessment of IgG responses to indigenous (autologous) and foreign

810 (heterologous) stool microbes in severe ME/CFS patients and matched healthy household

811 controls. (B) Level of IgG in serum of severe ME/CFS patients  $(n=5)$  and household control

812  $(n=5)$  binding to stool microbes from patient and control stool samples in vitro. (C) Levels of



815



825 followed by discrimination of singlets from doublets. SYBR+ microbes were discriminated 826 from auto fluorescent debris and collected for profiling of all stool microbes. IgG positive 827 and IgG negative populations were sorted from  $SYBR$ + events. (C) Pairwise comparisons of 828 observed richness of IgG positive and IgG negative microbes in severe ME/CFS patients 829  $(n=5)$  and matched household controls  $(n=5)$ . Analyses were performed at the species-level 830 reads rarefied to the lowest sequencing depth. P values were measured using two-tailed 831 paired t-tests. (D) Beta diversity of IgG positive species (filled shapes) and IgG negative 832 species (unfilled shapes) in severe ME/CFS patients (circles) and household controls 833 (squares). Beta-diversity was calculated using Bray-Curtis dissimilarity, presented on a non-834 metric multi-dimensional scaling (NMDS) plot.

835

- 836 FIGURE 7. Probability of serum IgG binding to autologous stool microbes from severe
- 837 ME/CFS patients ( $n=5$ ) and matched household controls ( $n=5$ ). IgG probability ratios for
- 838 species detected in all participants stool samples.
- 
- 840 SUPPLEMENTARY FIGURE 1. Study participant recruitment pathway. Severe ME patients
- 841 were recruited from the CFS clinic at Epsom and St Helier University Hospitals (ESTH),
- 842 Carshalton, UK and the ME/CFS service at East Coast Community Healthcare Centre,

843 Lowestoft, UK.

844

845 SUPPLEMENTARY FIGURE 2. Stool microbial load. Flow cytometric analysis of SYBR

846 Green+ microbial load in stool samples of severe ME/CFS patients  $(n=5)$  and matched

847 household controls  $(n=5)$ .

848

849 SUPPLEMENTARY FIGURE 3. Stool microbiome profiling of severe ME/CFS patients

850  $(n=5)$  and matched household controls  $(n=5)$ . (A) Relative microbiome profiling (RMP) at

851 the genus-level. (B) quantitative microbiome profiling (QMP, cells per gram of faeces) at the

852 genus-level. (C) RMP at the species-level. (D) QMP at the species-level.

853

854 SUPPLEMENTARY FIGURE 4. Pairwise alpha- and beta-diversity comparisons of the stool 855 microbiomes of severe ME/CFS patients  $(n=5)$  and matched household controls  $(n=5)$ . <sup>856</sup>Analyses were performed at the species-level on shotgun metagenomics data from SYBR+ 857 stool microbes. (A) Alpha diversity measures of Shannon index, inverse Simpson index and 858 richness based on reads rarefied to the lowest sequencing depth. P values were measured





871 stool microbiome in severe ME/CFS patients (circles) (n=5) and matched household controls

872 (squares)  $(n=5)$ . Pair numbers are depicted on the graphs but were not used in analysis.



A















household control

 $\overline{2}$ 

1

3  $^{+}$  $\overline{A}$ ⊠ 5

severe ME/CFS

Species